FRR Shares (Makes you Realise)

Equity

Home/ Are You A Trader/ Market Info/ Company Profile/ Smart Quotes

COMPANY PROFILE

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo

BSE1342.1038.9 (+2.98 %)

PREV CLOSE (Rs.) 1303.20

OPEN PRICE (Rs.) 1349.75

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 48797

TODAY'S LOW / HIGH (Rs.)1326.90 1359.00

52 WK LOW / HIGH (Rs.)994.35 1330.9

NSE1342.1037.7 (+2.89 %)

PREV CLOSE( Rs. ) 1304.40

OPEN PRICE (Rs.) 1332.20

BID PRICE (QTY) 1342.10 (70)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 2595497

TODAY'S LOW / HIGH(Rs.) 1325.90 1359.90

52 WK LOW / HIGH (Rs.)1010 1330

More From Company Profile

Smart Quotes

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Trade Value (Rs. in Lacs)

657.47

Dividend Yield(%)

0.00

TTM EPS (Rs.)

36.69

P/E Ratio

36.58

Book Value (Rs.)

379.18

Face Value (Rs.)

MCap (Rs. in Mn)

779493.86

Price/Earning (TTM)

31.97

Price/Sales (TTM)

7.07

Price/Book (MRQ)

3.54

PAT Margin (%)

15.72

ROCE (%)

10.85

Incorporation Year : 26-12 1986

Management Info :

Mangalam Ramasubramanian Kumar - Chairman K Nityananda Reddy - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : 040-23736370 / 23747340

Email : info@aurobindo.com

Website : www.aurobindo.com

Registrars Details :

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

20Mar Aurobindo Pharma’s arm gets EIR for Te
Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma has receiv..

20Mar Aurobindo Pharma informs about updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclos..

20Mar Aurobindo Pharma soars as its arm gets
Aurobindo Pharma is currently trading at Rs. 1281.90, up by 33.95 points..

Financials

	QTR Dec 25	ANNUAL 25
Net Profit	5820.7	17467.9
Gross Profit	7819	23584.5
Operating Profit	9196.3	28856.9
Net Sales	27472.8	109333

Rs. in Millions

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)

12604.90 (4.93%)

M.Cap (Rs. in Cr)16171.95

Abbott India (BSE)

26491.85 (2.19%)

M.Cap (Rs. in Cr)56293.33

Sanofi Cons. Health (BSE)

4540.95 (5.75%)

M.Cap (Rs. in Cr)10458.09

Bharat Parenterals (BSE)

1045.00 (16.08%)

M.Cap (Rs. in Cr)720.21

Shareholding Pattern

	PROMOTERS	51.82%
	MUTUAL FUNDS/UTI	19.52%
	NON-INSTITUTION	6.56%
	FI/BANKS/INSURANCE	5.5%
	GOVERNMENT	0%
	FII	0%

Mf Holding

Scheme Name

Hold(%)

Quant Manufacturing...

8.09

Quant Mid Cap Fund(G)

7.41

Mirae Asset Healthc...

6.67

ICICI Pru Pharma He...

6.06

Quant Large & Mid C...

5.89

Quant Healthcare Fu...

5.80

Tata India Pharma &...

5.44

Attention Investors

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month, Issued in the interest of Investors.

Risk Disclosure on Derivatives | Smart ODR | Mandatory Display | KYC Validation Links

BSE / NSE SEBI Registration No. INZ000279232, Depository Participant SEBI Registration No. – IN DP CDSL 132-2015

Mutual funds - ARN No. 81648 , Investment Adviser SEBI Registration No. : INA000008668.

CLOSE X

Risk Disclosures On Derivatives

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22

AUROBINDO PHARMA LTD.

Smart Quotes

Attention Investors

Download Client Registration Documents

Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don't's) in Vernacular Language :

Filing complaints on SCORESEasy & quick

Risk Disclosures On Derivatives